393 related articles for article (PubMed ID: 12776001)
1. Tegaserod and other serotonergic agents: what is the evidence?
Chey WD
Rev Gastroenterol Disord; 2003; 3 Suppl 2():S35-40. PubMed ID: 12776001
[TBL] [Abstract][Full Text] [Related]
2. Drug therapy options for patients with irritable bowel syndrome.
Talley NJ
Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911
[TBL] [Abstract][Full Text] [Related]
3. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
Moskwa A; Boznańska P
Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
[TBL] [Abstract][Full Text] [Related]
4. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
Beglinger C
Int J Clin Pract; 2002; 56(1):47-51. PubMed ID: 11831835
[TBL] [Abstract][Full Text] [Related]
5. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
Farthing MJ
Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
[TBL] [Abstract][Full Text] [Related]
6. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome.
Humphrey PP; Bountra C; Clayton N; Kozlowski K
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():31-8. PubMed ID: 10429738
[TBL] [Abstract][Full Text] [Related]
7. Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.
Johanson JF
Neurogastroenterol Motil; 2004 Dec; 16(6):701-11. PubMed ID: 15601419
[TBL] [Abstract][Full Text] [Related]
8. Tegaserod for constipation-predominant irritable bowel syndrome.
Kale-Pradhan PB; Wilhelm SM
Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
[TBL] [Abstract][Full Text] [Related]
9. Tegaserod for the treatment of constipation-predominant irritable bowel syndrome.
Baker DE
Rev Gastroenterol Disord; 2001; 1(4):187-98. PubMed ID: 12120185
[TBL] [Abstract][Full Text] [Related]
10. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
Lembo T; Wright RA; Bagby B; Decker C; Gordon S; Jhingran P; Carter E;
Am J Gastroenterol; 2001 Sep; 96(9):2662-70. PubMed ID: 11569692
[TBL] [Abstract][Full Text] [Related]
11. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
De Ponti F; Tonini M
Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
[TBL] [Abstract][Full Text] [Related]
12. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients.
Mangel AW; Northcutt AR
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():77-82. PubMed ID: 10429745
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.
Wolfe SG; Chey WY; Washington MK; Harding J; Heath AT; McSorley DJ; Dukes GE; Hunt CM
Am J Gastroenterol; 2001 Mar; 96(3):803-11. PubMed ID: 11280555
[TBL] [Abstract][Full Text] [Related]
14. Therapy for irritable bowel syndrome.
Lacy BE
N Engl J Med; 2004 Mar; 350(12):1261-3; author reply 1261-3. PubMed ID: 15031865
[No Abstract] [Full Text] [Related]
15. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
Rahimi R; Nikfar S; Abdollahi M
Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological treatment of irritable bowel syndrome--from concept to sales.
Kamm MA
Eur J Surg Suppl; 2002; (587):10-5. PubMed ID: 16144196
[TBL] [Abstract][Full Text] [Related]
17. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
Lewis JH
Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):13-29. PubMed ID: 20136586
[TBL] [Abstract][Full Text] [Related]
18. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.
Watson ME; Lacey L; Kong S; Northcutt AR; McSorley D; Hahn B; Mangel AW
Am J Gastroenterol; 2001 Feb; 96(2):455-9. PubMed ID: 11232690
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
Camilleri M; Northcutt AR; Kong S; Dukes GE; McSorley D; Mangel AW
Lancet; 2000 Mar; 355(9209):1035-40. PubMed ID: 10744088
[TBL] [Abstract][Full Text] [Related]
20. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome.
Viramontes BE; Camilleri M; McKinzie S; Pardi DS; Burton D; Thomforde GM
Am J Gastroenterol; 2001 Sep; 96(9):2671-6. PubMed ID: 11569693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
